The lease is a binary bet on FDA approval of Deramiocel by year-end 2026. If approved, Capricor gains manufacturing capacity for commercial launch; if not, the lease can be terminated without penalty. Monitor FDA action date and any PDUFA updates for Deramiocel.
Price Chart
Executive Summary
Capricor Therapeutics entered into a lease for a new 171,000 sq ft headquarters in San Diego, with monthly base rent of ~$958,000 and an 18-month full rent abatement. The lease is contingent on FDA approval of Deramiocel for Duchenne muscular dystrophy by December 31, 2026, or either party may terminate. This creates a significant financial obligation tied to a binary regulatory catalyst.
Key Facts
- Lease for ~171,000 rentable square feet at 9625 Towne Centre Drive, San Diego, for new HQ including expanded manufacturing cleanrooms and R&D lab.
- Initial monthly base rent ~$958,000 ($5.60/sq ft), subject to 3.0% annual increases.
- 18-month full base rent abatement from rent commencement date, followed by 6-month partial abatement on 128,068 sq ft.
- Lease term ends 138 months from first full month after rent commencement.
- Lease commencement contingent on FDA approval of Deramiocel for Duchenne muscular dystrophy by December 31, 2026, or either party may terminate.
- Security deposit of ~$958,000 in cash or letter of credit required.
- Capricor responsible for real property taxes, insurance, maintenance, and operating costs.
Financial Impact
Monthly base rent of ~$958,000, escalating 3% annually, with total lease obligation over 11.5 years (138 months) exceeding $100M before abatements. Security deposit of ~$958,000.
Risk Factors
- FDA non-approval of Deramiocel by December 31, 2026 could trigger lease termination, but no penalty beyond lost tenant improvement allowance.
- Large lease obligation (~$958K/month) could strain cash reserves if commercial launch is delayed.
- Execution risk in building out 171,000 sq ft cleanroom and lab space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-083559 |
| Document: 0001104659-26-083559-index-headers.html | 0001104659-26-083559 |
| Document: 0001104659-26-083559-index.html | 0001104659-26-083559 |
| Document: 0001104659-26-083559.txt | 0001104659-26-083559 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G/A | $7.27 $6.13 | ▲ +15.68% | ▲ +14.67% | $6.10 (+16.09%) |
Aug 24, 2026 9w ago | 8-K | $6.80 $9.91 | ▼ −45.74% | ▼ −45.27% | $6.10 (+10.29%) |
Aug 21, 2026 9w ago | Institutional Cluster | $6.29 $9.59 | ▲ +52.46% | ▲ +51.99% | $6.10 (−3.02%) |
Jul 30, 2026 12w ago | Press Release | $4.19 $4.18 | ▲ +0.24% | ▲ +3.86% | $6.10 (−45.58%) |
Jul 14, 2026 15w ago | 8-K | $20.35 $18.91 | ▼ −7.08% | ▼ −6.10% | $6.10 (−70.02%) |
Jun 29, 2026 17w ago | Insider Cluster | $24.08 $22.43 | ▼ −6.85% | ▼ −7.46% | $6.10 (−74.67%) |
Jun 26, 2026 17w ago | 8-K | $23.80 $22.43 | ▼ −5.76% | ▼ −7.14% | $6.10 (−74.37%) |
Jun 24, 2026 17w ago | Insider Cluster | $30.40 $23.07 | ▼ −24.11% | ▼ −25.67% | $6.10 (−79.93%) |
Jun 1, 2026 21w ago | Court Ruling | $27.34 $26.01 | ▼ −4.86% | ▼ −1.90% | $6.10 (−77.69%) |
May 12, 2026 24w ago | Press Release | $30.33 $26.92 | ▼ −11.24% | ▼ −10.09% | $6.10 (−79.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers